ME00091B - C-aril glukozid sglt2 inhibitori i postupak za njihovu upotrebu - Google Patents

C-aril glukozid sglt2 inhibitori i postupak za njihovu upotrebu

Info

Publication number
ME00091B
ME00091B MEP-2008-130A MEP2008130A ME00091B ME 00091 B ME00091 B ME 00091B ME P2008130 A MEP2008130 A ME P2008130A ME 00091 B ME00091 B ME 00091B
Authority
ME
Montenegro
Prior art keywords
inhibitor
agent
mixture
compound
agents
Prior art date
Application number
MEP-2008-130A
Other languages
English (en)
French (fr)
Unknown language (me)
Inventor
Bruce Ellsworth
William N Washburn
Philip M Sher
Gang Wu
Wei Meng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29582046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00091(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ME00091B publication Critical patent/ME00091B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-2008-130A 2002-05-20 2003-05-15 C-aril glukozid sglt2 inhibitori i postupak za njihovu upotrebu ME00091B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/151,436 US6515117B2 (en) 1999-10-12 2002-05-20 C-aryl glucoside SGLT2 inhibitors and method
PCT/US2003/015591 WO2003099836A1 (en) 2002-05-20 2003-05-15 C-aryl glucoside sglt2 inhibitors and method

Publications (1)

Publication Number Publication Date
ME00091B true ME00091B (me) 2010-10-10

Family

ID=29582046

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2008-130A ME00091B (me) 2002-05-20 2003-05-15 C-aril glukozid sglt2 inhibitori i postupak za njihovu upotrebu
MEP-130/08A MEP13008A (en) 2002-05-20 2003-05-15 C-aryl glucoside sglt2 inhibitors and method

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-130/08A MEP13008A (en) 2002-05-20 2003-05-15 C-aryl glucoside sglt2 inhibitors and method

Country Status (39)

Country Link
US (1) US6515117B2 (enExample)
EP (1) EP1506211B1 (enExample)
JP (4) JP5090621B2 (enExample)
KR (1) KR101021752B1 (enExample)
CN (5) CN101628905B (enExample)
AR (1) AR040032A1 (enExample)
AT (1) ATE353334T1 (enExample)
AU (1) AU2003237886B2 (enExample)
BE (2) BE2013C025I2 (enExample)
BR (2) BRPI0311323B8 (enExample)
CA (1) CA2486539C (enExample)
CY (3) CY1106465T1 (enExample)
DE (1) DE60311649T2 (enExample)
DK (1) DK1506211T3 (enExample)
ES (1) ES2280759T3 (enExample)
FR (2) FR13C0022I2 (enExample)
GE (1) GEP20084403B (enExample)
HK (1) HK1205120A1 (enExample)
HR (1) HRP20041084B1 (enExample)
IL (1) IL165119A0 (enExample)
IN (1) IN2004DE03573A (enExample)
IS (1) IS7529A (enExample)
LT (1) LTC1506211I2 (enExample)
LU (2) LU92182I2 (enExample)
ME (2) ME00091B (enExample)
MX (1) MX249731B (enExample)
MY (1) MY142499A (enExample)
NO (4) NO329107B1 (enExample)
NZ (1) NZ536605A (enExample)
PE (1) PE20040760A1 (enExample)
PL (1) PL210304B1 (enExample)
PT (1) PT1506211E (enExample)
RS (1) RS51469B (enExample)
RU (4) RU2337916C2 (enExample)
SI (1) SI1506211T1 (enExample)
TW (1) TWI310770B (enExample)
UA (1) UA77306C2 (enExample)
WO (1) WO2003099836A1 (enExample)
ZA (1) ZA200409295B (enExample)

Families Citing this family (348)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) * 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
FR2809310B1 (fr) * 2000-05-26 2004-02-13 Centre Nat Rech Scient Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
EP1345602B1 (en) 2000-11-30 2010-07-21 Novodermix International Limited Wound healing
ES2326911T3 (es) * 2001-02-24 2009-10-21 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Derivados de xantina para uso como medicamentos, asi como su procedimiento de preparacion.
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CN100577175C (zh) * 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
ATE318272T1 (de) * 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
WO2003020737A1 (en) * 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
TWI254635B (en) * 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2003272903A1 (en) 2002-10-04 2004-04-23 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
DE10258007B4 (de) * 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
BR0317929A (pt) * 2003-01-03 2006-04-11 Bristol Myers Squibb Co métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
CN1802366B (zh) 2003-03-14 2010-12-22 安斯泰来制药有限公司 C-糖苷衍生物及其盐
JP2004300102A (ja) * 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
TWI385177B (zh) * 2003-08-01 2013-02-11 Mitsubishi Tanabe Pharma Corp 吡喃葡萄糖基衍生物及其製造方法
EP1680414A4 (en) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED INDAZOLE-O-GLUCOSIDE
EA011515B1 (ru) * 2003-08-01 2009-04-28 Янссен Фармацевтика Н.В. Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
AU2004261660A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic C-glycosides
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
CA2549025A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2557320C (en) * 2004-03-04 2013-02-05 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivatives for prevention or treatment of hyperglycemia
ES2387881T3 (es) 2004-03-16 2012-10-03 Boehringer Ingelheim International Gmbh Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparación
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
DE102004034690A1 (de) * 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
CA2574451A1 (en) * 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US20080139484A1 (en) * 2004-09-29 2008-06-12 Kissei Pharmaceutical Co., Ltd. 1(Beta-D-Glycopyranosyl)-3-Substituted Nitrogenous Heterocyclic Compound, Medicinal Composition Containing the Same, and Medicinal Use Thereof
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US20090036355A1 (en) * 2004-10-13 2009-02-05 Sanjay Bhanot Antisense Modulation of PTP1B Expression
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2587639A1 (en) * 2004-12-16 2006-06-22 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
MY147375A (en) * 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
ES2319461T3 (es) * 2005-02-10 2009-05-07 Bristol-Myers Squibb Company Dihidroquinazolinonas como moduladores de 5ht.
DE602006009772D1 (de) * 2005-02-23 2009-11-26 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
ATE453656T1 (de) * 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) * 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) * 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
WO2007014894A2 (en) * 2005-07-27 2007-02-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted ( (hetero) cycloalyklethynyl-benzyl) -benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
JP2009502959A (ja) * 2005-07-28 2009-01-29 ブリストル−マイヤーズ スクイブ カンパニー セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
DE602006017566D1 (de) * 2005-08-30 2010-11-25 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
RU2008113050A (ru) * 2005-09-08 2009-10-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
AR056195A1 (es) * 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
JP5094416B2 (ja) * 2005-12-28 2012-12-12 武田薬品工業株式会社 糖尿病治療剤
EA200801773A1 (ru) 2006-02-15 2009-02-27 Бёрингер Ингельхайм Интернациональ Гмбх Глюкопиранозилзамещенные производные бензонитрила, фармацевтические композиции, содержащие такие соединения, их применение и способ их получения
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
WO2007143052A1 (en) * 2006-06-01 2007-12-13 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
DE102006028862A1 (de) 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
JP5384343B2 (ja) 2006-08-15 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、ｓｇｌｔ阻害剤としてのそれらの使用及びそれらの製造方法
SI2066344T1 (sl) * 2006-09-07 2011-09-30 Glaxosmithkline Biolog Sa Inaktivirano poliovirusno kombinirano cepivo
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
AU2007307544A1 (en) * 2006-10-13 2008-04-17 Chugai Seiyaku Kabushiki Kaisha Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
US8283326B2 (en) 2006-10-27 2012-10-09 Boehringer Ingelheim International Gmbh Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
ES2397664T3 (es) * 2006-12-04 2013-03-08 Janssen Pharmaceutica, N.V. Derivados de glucopiranósilo que contienen tienilo como antidiabéticos
KR20090097184A (ko) 2006-12-06 2009-09-15 스미스클라인 비참 코포레이션 비시클릭 화합물 및 항당뇨병제로서의 용도
EP2105442A4 (en) 2006-12-21 2013-01-23 Astellas Pharma Inc PROCESS FOR PREPARING A C-GLYCOSIDE DERIVATIVE AND SYNTHETIC INTERMEDIATE PRODUCT THEREFOR
DE102007008420A1 (de) 2007-02-21 2008-08-28 Merck Patent Gmbh Benzimidazolderivate
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
AU2014201239B2 (en) * 2007-03-22 2016-03-10 Astrazeneca Ab Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PT2183263E (pt) * 2007-07-26 2012-01-11 Lexicon Pharmaceuticals Inc Processos e compostos úteis na preparação de inibidores do co-transportador 2 de glucose e sódio
CL2008002425A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
CN101784278A (zh) * 2007-08-17 2010-07-21 贝林格尔.英格海姆国际有限公司 用于治疗fab-相关的疾病的嘌呤衍生物
RU2497526C2 (ru) 2007-08-23 2013-11-10 Теракос, Инк. Производные бензилбензола и способы их применения
CA2699285C (en) * 2007-09-10 2016-12-13 Ahmed F. Abdel-Magid Process for the preparation of compounds useful as inhibitors of sodium-dependent glucose transporter (sglt)
DE102007048716A1 (de) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
CA2706018C (en) * 2007-11-30 2015-11-24 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CN104387354A (zh) * 2007-12-27 2015-03-04 阿斯利康公司 Sglt2 抑制剂的晶体结构及其制备方法
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
CN101969944B (zh) * 2008-01-31 2013-04-10 安斯泰来制药有限公司 脂肪性肝病的治疗用医药组合物
CN101503399B (zh) * 2008-02-04 2012-06-27 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
DE102008017590A1 (de) 2008-04-07 2009-10-08 Merck Patent Gmbh Glucopyranosidderivate
WO2009143010A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating hyponatremia employing an sglt2 inhibitor and composition containing same
US8603989B2 (en) * 2008-05-22 2013-12-10 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
MX2010012656A (es) 2008-05-22 2010-12-20 Squibb Bristol Myers Co Metodo para tratar la hiperuricemia empleando un inhibidor de sglt2 y composicion que contiene el mismo.
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
TWI523652B (zh) * 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
AR073118A1 (es) * 2008-08-22 2010-10-13 Theracos Inc Procesos para la preparacion de inhibidores de sglt2 y formas cristalinas del mismo.
KR101338540B1 (ko) * 2008-08-28 2013-12-06 화이자 인코포레이티드 다이옥사-바이사이클로[3.2.1]옥테인-2,3,4-트라이올 유도체
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
KR20110055740A (ko) * 2008-09-19 2011-05-25 노파르티스 아게 글리코시드 유도체 및 그의 용도
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
UA106365C2 (ru) * 2009-02-13 2014-08-26 Берингер Ингельхайм Интернациональ Гмбх Способ улучшения гликемического контроля и способ снижения жира в организме с применением ингибитора sglt-2
AP2011005794A0 (en) * 2009-02-13 2011-08-31 Boehringer Ingelheim Int Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a furtherantidiabetic agent and uses thereof.
FI2395968T3 (fi) * 2009-02-13 2024-02-27 Boehringer Ingelheim Int Glukopyranosylidifenylimetaanijohdannaisia sisältävä farmaseuttinen koostumus, niiden farmaseuttinen annostusmuoto, niiden valmistusmenetelmä ja niiden käyttö potilaan glukemiasäädön parantamiseksi
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
JP5505741B2 (ja) * 2009-02-23 2014-05-28 大正製薬株式会社 Ｓｇｌｔ１阻害剤としての４−イソプロピルフェニルグルシトール化合物
EP2226076A1 (de) 2009-02-25 2010-09-08 Henning Vollert Pflanzlicher Extrakt zur Prophylaxe und Behandlung von hyperglykämischen Erkrankungen
ES2460019T3 (es) * 2009-03-31 2014-05-13 Boehringer Ingelheim International Gmbh Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de PDE9A
JP2012528170A (ja) * 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
HRP20130561T1 (en) 2009-07-10 2013-07-31 Janssen Pharmaceutica Nv CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
PL2483286T3 (pl) * 2009-09-30 2017-04-28 Boehringer Ingelheim International Gmbh Sposób wytwarzania postaci krystalicznej 1-chloro-4-(β-D-glukopiranoz-1-ylo)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzylo]-benzenu
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
KR101730920B1 (ko) * 2009-10-14 2017-04-27 얀센 파마슈티카 엔.브이. Ｓｇｌｔ2의 억제제로서 유용한 화합물의 제조 방법
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
KR101426180B1 (ko) 2009-11-02 2014-07-31 화이자 인코포레이티드 디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
RS57926B1 (sr) 2009-11-13 2019-01-31 Astrazeneca Ab Formulacije tablete sa trenutnim oslobađanjem
LT2498758T (lt) 2009-11-13 2018-11-26 Astrazeneca Ab Dvisluoksnės tabletės formuluotės
CA2779088A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
AR079438A1 (es) 2009-12-09 2012-01-25 Panacea Biotec Ltd Derivados de azucar, composiciones farmaceuticas y sus usos
CN102134226B (zh) * 2010-01-26 2013-06-12 天津药物研究院 一类苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20140088027A1 (en) * 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
EP2568971B1 (en) 2010-05-11 2020-10-14 Mitsubishi Tanabe Pharma Corporation Canagliflozin containing tablets
HRP20161231T1 (hr) 2010-05-11 2016-11-04 Janssen Pharmaceutica N.V. Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
EP2603511B1 (en) 2010-08-12 2017-03-15 Boehringer Ingelheim International GmbH 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
MX2013002146A (es) 2010-09-03 2013-04-03 Astrazeneca Uk Ltd Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua.
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
MX2013008372A (es) 2011-02-01 2013-08-12 Astrazeneca Uk Ltd Formulaciones farmaceuticas que incluyen compuesto de amina.
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN102643256B (zh) 2011-02-18 2014-12-24 上海璎黎科技有限公司 一种芳基糖苷类化合物及其制备方法和应用
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CN102167715B (zh) * 2011-03-07 2013-04-24 上海惠斯生物科技有限公司 一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
US10544135B2 (en) 2011-04-13 2020-01-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
CN102757415B (zh) * 2011-04-25 2015-07-29 北京普禄德医药科技有限公司 一种钠依赖性葡萄糖转运蛋白抑制剂及其制备方法和用途
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
KR101961884B1 (ko) * 2011-05-26 2019-03-25 티에프켐 아릴, 헤테로아릴, 오-아릴 및 오-헤테로 아릴 족 카르바슈가
CA2837627A1 (en) 2011-06-03 2012-12-06 Boehringer Ingelheim International Gmbh Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
EP2529742B1 (en) 2011-06-03 2013-11-20 ratiopharm GmbH Pharmaceutical composition comprising dapagliflozin and cyclodextrin
CA2837232A1 (en) 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
EP2725031B1 (en) 2011-06-25 2016-08-03 Xuanzhu Pharma Co., Ltd. C-glycoside derivatives
US20130035298A1 (en) 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9018249B2 (en) 2011-09-13 2015-04-28 Panacea Biotec Limited SGLT inhibitors
BR112014010574A2 (pt) * 2011-10-31 2017-05-02 Scinopharm Taiwan Ltd formas cristalinas e não cristalinas de inibidores sglt2
EP2597090A1 (en) * 2011-11-28 2013-05-29 Sandoz AG Crystalline dapagliflozin hydrate
PL2794626T6 (pl) 2011-12-22 2020-11-02 Glycomimetics, Inc. Związki antagonistyczne E-selektyny
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013178064A1 (zh) * 2012-05-29 2013-12-05 广东东阳光药业有限公司 吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
EP3549587A1 (de) 2012-06-30 2019-10-09 BioActive Food GmbH Zusammensetzung zur behandlung von hyperglykämischen erkrankungen
US9320727B2 (en) * 2012-08-30 2016-04-26 Taisho Pharmaceutical Co., Ltd Combinations of SGLT 2 inhibitors and antihypertensive drugs
ES2668045T3 (es) 2012-12-07 2018-05-16 Glycomimetics, Inc. Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas
CN103910769B (zh) 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP2774619B1 (de) 2013-03-04 2016-05-18 BioActive Food GmbH Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
WO2014159151A1 (en) 2013-03-14 2014-10-02 Msd International Gmbh Methods for preparing sglt2 inhibitors
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014161836A1 (en) 2013-04-04 2014-10-09 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE058731T2 (hu) 2013-04-18 2022-09-28 Boehringer Ingelheim Int Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai
EP2991999B1 (en) 2013-04-29 2019-05-08 Mapi Pharma Limited Dapagliflozin lactose co-crystal
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015040571A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Process for the preparation of dapagliflozin
US20160237054A1 (en) * 2013-09-27 2016-08-18 Sun Pharmaceutical Industries Limited Process for the purification of dapagliflozin
CN104513283B (zh) 2013-09-27 2018-01-16 广东东阳光药业有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
WO2015063726A1 (en) 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
AU2014364999B2 (en) 2013-12-17 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in feline animals
US9902751B2 (en) 2013-12-30 2018-02-27 Mylan Laboratories Limited Process for the preparation of empagliflozin
CN104761522B (zh) * 2014-01-03 2017-02-15 山东轩竹医药科技有限公司 光学纯的苄基‑4‑氯苯基的c‑糖苷衍生物
US9315438B2 (en) 2014-01-03 2016-04-19 Xuanzhu Pharma Co., Ltd Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
CN105960242A (zh) 2014-01-23 2016-09-21 勃林格殷格翰动物保健有限公司 犬科动物中代谢紊乱的治疗
CN103739581B (zh) * 2014-01-23 2016-11-23 中国药科大学 C-芳基葡萄糖苷sglt2抑制剂
CN104829572B (zh) * 2014-02-10 2019-01-04 江苏豪森药业集团有限公司 达格列净新晶型及其制备方法
IN2014MU00626A (enExample) * 2014-02-21 2015-09-25 Cadila Healthcare Ltd
WO2015128853A1 (en) 2014-02-28 2015-09-03 Sun Pharmaceutical Industries Limited Dapagliflozin compositions
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
IN2014CH01141A (enExample) * 2014-03-06 2015-09-11 Msn Lab Private Ltd
US10688116B2 (en) 2014-04-01 2020-06-23 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in equine animals
CN105001213B (zh) * 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
EP2944311A1 (de) 2014-05-16 2015-11-18 BioActive Food GmbH Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
ES2900843T3 (es) * 2014-05-16 2022-03-18 Astrazeneca Ab Método para suprimir la secreción de glucagón de un inhibidor de sglt2
US9676741B1 (en) 2014-06-23 2017-06-13 Sun Pharmaceutical Industries Limited Co-crystal of dapagliflozin with citric acid
MX2017003944A (es) 2014-09-25 2017-06-26 Astrazeneca Ab Combinacion de un acido graso omega-3 y un inhibidor de sglt-2 para tratar enfermedades hepaticas.
KR102539788B1 (ko) 2014-09-25 2023-06-07 베링거잉겔하임베트메디카게엠베하 말과 동물의 대사 장애를 예방하기 위한 sglt2 억제제와 도파민 작용제의 병용 치료
CN104327027B (zh) * 2014-10-14 2017-04-05 中国药科大学 一类新型c‑芳基葡萄糖苷sglt2抑制剂
CN104478839A (zh) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 一种达格列净的合成方法
CN104496952B (zh) * 2014-11-28 2017-04-19 深圳翰宇药业股份有限公司 一种达格列净的合成方法
CA2968391C (en) 2014-12-03 2022-04-26 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
CN105753910A (zh) * 2014-12-16 2016-07-13 康普药业股份有限公司 一种卡格列净中间体的制备方法
CN104529970A (zh) * 2015-01-08 2015-04-22 江苏联环药业股份有限公司 制备达格列净的方法
CN104478959A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
CN104478957A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
CN104530149A (zh) * 2015-01-14 2015-04-22 佛山市赛维斯医药科技有限公司 卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
CN104478968A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478966A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478963A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 一种含腈基苯s-葡萄糖苷结构的化合物及其用途
CN104497070A (zh) * 2015-01-15 2015-04-08 佛山市赛维斯医药科技有限公司 一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
CN104478965A (zh) * 2015-01-15 2015-04-01 佛山市赛维斯医药科技有限公司 一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
US10508128B2 (en) 2015-02-09 2019-12-17 Indoco Remedies Limited Process for the preparation of SGLT inhibitor compounds
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
WO2016161995A1 (en) 2015-04-08 2016-10-13 Zentiva, K.S. Solid forms of amorphous dapagliflozin
US10556877B2 (en) 2015-05-05 2020-02-11 Glenmark Life Sciences Limited Process for preparation of dapagliflozin
CN106317068A (zh) * 2015-06-23 2017-01-11 中国科学院上海药物研究所 一种c,o-螺环芳基糖苷类化合物及其制备和应用
CN104961715B (zh) * 2015-07-10 2017-08-22 浙江美诺华药物化学有限公司 一种达格列净的制备方法
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
US10428053B2 (en) 2015-09-15 2019-10-01 Laurus Labs Limited Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
CZ2015729A3 (cs) 2015-10-13 2017-04-26 Zentiva, K.S. Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
CN105218329B (zh) * 2015-10-15 2017-05-03 上海应用技术学院 一种列净类似物中间体及其制备方法
EP3362055B1 (en) 2015-10-15 2023-01-18 Boehringer Ingelheim International GmbH Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
US9845303B2 (en) 2015-10-19 2017-12-19 Cadila Healthcare Limited Process for the preparation of dapagliflozin
CN106892929B (zh) * 2015-12-17 2020-01-14 上海艾力斯医药科技有限公司 螺缩酮衍生物及其制备方法和应用
CN105693669A (zh) * 2015-12-28 2016-06-22 南昌大学 一种抗糖尿病化合物及其制备方法和用途
RU2739024C2 (ru) * 2016-01-04 2020-12-21 Че Иль Фармасьютикал Ко., Лтд. С-гликозидные производные, содержащие конденсированное фенильное кольцо, или их фармацевтически приемлемые соли, способ получения таковых и фармацевтическая композиция, содержащая таковые
WO2017118945A1 (en) 2016-01-08 2017-07-13 Lupin Limited Premix of dapagliflozin and process for the preparation thereof
US11045485B2 (en) 2016-01-22 2021-06-29 Glycomimetics, Inc. Glycomimetic inhibitors of PA-IL and PA-IIL lectins
US9834533B2 (en) * 2016-02-19 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing SGLT2 inhibitors and intermediates thereof
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
JP2019512537A (ja) 2016-03-31 2019-05-16 ルピン・リミテッド ダパグリフロジンの医薬組成物
CN107304194A (zh) * 2016-04-20 2017-10-31 扬子江药业集团上海海尼药业有限公司 制备达格列净的方法
EP3466939B1 (en) * 2016-05-24 2021-02-24 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. New dapagliflozin crystal form and preparation method and use thereof
WO2017203229A1 (en) 2016-05-27 2017-11-30 Cipla Limited Dapagliflozin premixes
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3497131B1 (en) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4.
ES2926403T3 (es) * 2016-08-09 2022-10-25 Laurus Labs Ltd Nuevos procedimientos para la preparación de dapagliflozina o sus solvatos o co-cristales de la misma
WO2018029264A1 (en) 2016-08-10 2018-02-15 Amneal Pharmaceuticals Company Gmbh Process for preparation of dapagliflozin and intermediates thereof
WO2018068010A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
MX2019004549A (es) 2016-10-19 2019-06-12 Boehringer Ingelheim Int Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
MX2019005435A (es) 2016-11-10 2019-07-10 Boehringer Ingelheim Int Composicion farmaceutica, metodos para tratamiento y sus usos.
KR20180058510A (ko) 2016-11-24 2018-06-01 한미약품 주식회사 다파글리플로진 l-프롤린을 포함하는 약제학적 제제
CN108218928B (zh) * 2016-12-13 2020-06-30 华润双鹤药业股份有限公司 葡萄糖苷的二环衍生物及其制备方法和用途
WO2018142422A1 (en) * 2017-02-02 2018-08-09 Indoco Remedies Limited Process for the preparation of dapagliflozin
WO2018169853A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
EP3621977A4 (en) 2017-05-09 2021-04-07 Piramal Pharma Limited SGLT2 INHIBITOR PREPARATION PROCESS AND ITS INTERMEDIARIES
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
BR112020010831A2 (pt) * 2017-11-30 2020-11-10 Idorsia Pharmaceuticals Ltd composição farmacêutica, aprocitentan, e, método
JP7275131B2 (ja) 2017-11-30 2023-05-17 グリコミメティクス， インコーポレイテッド 骨髄浸潤リンパ球を動員する方法、およびその使用
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
EP3761994A1 (en) 2018-03-05 2021-01-13 GlycoMimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
EP3810623A1 (en) 2018-06-25 2021-04-28 Pharmathen S.A. A novel process for the preparation of sglt-2 inhibitors
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
KR102131359B1 (ko) 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
KR102812426B1 (ko) 2018-10-29 2025-05-26 베링거 인겔하임 인터내셔날 게엠베하 피리디닐 설폰아미드 유도체, 약제학적 조성물 및 이의 용도
WO2020089025A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN109705075B (zh) * 2018-12-13 2022-12-23 苏中药业集团股份有限公司 一种达格列净的纯化方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
SG11202003971RA (en) 2019-08-30 2021-04-29 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
AU2020394498A1 (en) 2019-11-28 2022-06-09 Boehringer Ingelheim Vetmedica Gmbh Use of SGLT-2 inhibitors in the drying-off of non-human mammals
MX2022010090A (es) 2020-02-17 2022-09-02 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
WO2021165316A1 (en) 2020-02-21 2021-08-26 Zakłady Farmaceutyczne POLPHARMA S.A. Pharmaceutical composition comprising dapagliflozin
WO2021176096A1 (en) 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor
TWI865738B (zh) 2020-03-06 2024-12-11 美商維泰克斯製藥公司 治療apol-1依賴性局灶性節段性腎小球硬化之方法
JP2023523596A (ja) 2020-04-22 2023-06-06 バイエル アクチェンゲゼルシャフト 心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ
US20230165856A1 (en) 2020-04-29 2023-06-01 Astrazeneca Ab Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
CN115867538A (zh) 2020-06-05 2023-03-28 新梅斯托克公司 高纯的无定形达格列净的制备
WO2021260617A1 (en) * 2020-06-25 2021-12-30 Hikal Limited An improved process for preparation of dapagliflozin propanediol monohydrate
BR112023000406A2 (pt) 2020-07-10 2023-01-31 Astrazeneca Ab Combinação de zibotentan e dapagliflozina
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
WO2022051316A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
EP4206212A4 (en) 2020-09-30 2024-05-22 Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. SGLT-2 AND SARCOSINE INHIBITOR COCRYSTAL, PROCESS FOR PREPARATION THEREFOR AND USE THEREOF
TR202019590A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
TR202019592A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Amorf dapagliflozinin katı farmasötik formülasyonları
WO2022119543A1 (en) 2020-12-03 2022-06-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
TR202019589A2 (tr) 2020-12-03 2022-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
US20240212818A1 (en) 2021-04-01 2024-06-27 Astrazeneca Uk Limited Systems and methods for managing prediabetes with a gliflozin sodiumglucose cotransport 2 inhibitor pharmaceutical composition
EP4079296A1 (en) 2021-04-21 2022-10-26 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
MX2024001184A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
JP2024525981A (ja) 2021-07-28 2024-07-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN113773194B (zh) 2021-08-16 2023-05-02 浙江奥翔药业股份有限公司 作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
IL314031A (en) 2021-12-30 2024-09-01 Newamsterdam Pharma B V Obicetrapib and sglt2 inhibitor combination
EP4212150A1 (en) 2022-01-13 2023-07-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet composition comprising amorphous dapagliflozin and metformin
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
CA3256728A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING SGLT-2 INHIBITORS
IL317183A (en) 2022-06-07 2025-01-01 Astrazeneca Ab Combinations of RXFP1 modulators and SGLT2 inhibitors
KR102490653B1 (ko) * 2022-08-03 2023-01-20 진양제약주식회사 다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
KR20240028315A (ko) 2022-08-24 2024-03-05 주식회사 제뉴원사이언스 다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
EP4661873A1 (en) 2023-02-08 2025-12-17 Astrazeneca AB Combination of zibotentan and dapagliflozin for the treatment of high proteinuria chronic kidney disease
TW202500160A (zh) 2023-03-06 2025-01-01 德商百靈佳殷格翰維美迪加股份有限公司 用於遞送特別是包含一或多種ｓｇｌｔ—２抑制劑之液體醫藥組合物之系統及方法
EP4427742A1 (en) 2023-03-06 2024-09-11 Galenicum Health S.L.U. Pharmaceutical compositions comprising dapagliflozin and metformin
EP4431088A1 (en) 2023-03-06 2024-09-18 Galenicum Health S.L.U. Pharmaceutical compositions comprising dapagliflozin and metformin
WO2024210557A1 (ko) 2023-04-05 2024-10-10 한미약품 주식회사 개선된 안정성과 용출률이 확보된 사쿠비트릴-발사르탄 및 sglt-2 억제제를 포함하는 복합제제
AR132497A1 (es) 2023-04-24 2025-07-02 Newamsterdam Pharma B V Combinación de obicetrapib amorfo e inhibidor de sglt2
WO2024240632A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
EP4487910A1 (en) 2023-07-06 2025-01-08 Zaklady Farmaceutyczne Polpharma S.A. Process for the preparation of dapagliflozin
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
EP4556001A1 (en) 2023-11-14 2025-05-21 Sanovel Ilac Sanayi ve Ticaret A.S. A bilayer tablet composition comprising dapagliflozin and metformin
WO2025125513A1 (en) 2023-12-15 2025-06-19 AstraZeneca Ireland Limited Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension
WO2025133907A1 (en) 2023-12-18 2025-06-26 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of microvascular angina
WO2025160910A1 (en) * 2024-02-01 2025-08-07 New Wish Biotechnology Wuxi Co., Ltd. Indazole compound and pharmaceutical composition, preparation method and use thereof
WO2025163559A1 (en) 2024-02-01 2025-08-07 Astrazeneca Ab Combination of zibotentan and dapagliflozin for use for the treatment of hypertension
CN118908926A (zh) * 2024-07-24 2024-11-08 安徽海康药业股份有限公司 一种达格列净的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03133746A (ja) * 1989-10-19 1991-06-06 Taiyo Kagaku Kogyo Kk 自立袋およびその製造方法
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
WO1994011030A1 (en) * 1992-11-13 1994-05-26 The Ohio State University Research Foundation C-glycoside analogues of n-(4-hydroxyphenyl)retinamide-o-glucuronide
US5444050A (en) * 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
EP0850948B1 (en) 1996-12-26 2002-04-24 Tanabe Seiyaku Co., Ltd. Propiophenone derivatives and process for preparing the same
WO1998031697A1 (en) 1997-01-15 1998-07-23 Sankyo Company, Limited Aryl c-glycoside compounds and sulfated esters thereof
JPH10245391A (ja) 1997-03-03 1998-09-14 Dainippon Ink & Chem Inc ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
EP1002792B1 (en) * 1997-04-04 2004-07-14 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JP3451000B2 (ja) 1997-10-20 2003-09-29 新日本製鐵株式会社 方向性珪素鋼板の絶縁皮膜形成方法
DE19806803A1 (de) * 1998-02-18 1999-11-25 Hermann Koepsell Transporter für Saccharid-gekoppelte Zytostatika in Tumorzellen
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
US6486299B1 (en) 1998-09-28 2002-11-26 Curagen Corporation Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
AUPP823099A0 (en) * 1999-01-18 1999-02-11 Alchemia Pty Ltd Protecting groups for carbohydrate synthesis
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
ATE318272T1 (de) * 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren

Also Published As

Publication number Publication date
CN101628905A (zh) 2010-01-20
EP1506211B1 (en) 2007-02-07
MX249731B (es) 2007-10-01
RU2008122558A (ru) 2009-12-20
RU2017131447A (ru) 2019-03-07
FR14C0054I1 (fr) 2014-08-08
CY2014025I1 (el) 2015-11-04
CN104230866A (zh) 2014-12-24
EP1506211A1 (en) 2005-02-16
RS99204A (sr) 2006-12-15
IL165119A0 (en) 2005-12-18
RU2746132C1 (ru) 2021-04-07
NZ536605A (en) 2007-05-31
MEP13008A (en) 2010-06-10
GEP20084403B (en) 2008-06-25
HK1068214A1 (en) 2005-04-22
BRPI0311323B1 (pt) 2017-09-26
RU2013115635A (ru) 2014-10-20
AR040032A1 (es) 2005-03-09
NO2013007I2 (no) 2013-04-12
PT1506211E (pt) 2007-04-30
NO20044915L (no) 2004-12-16
RU2489151C3 (ru) 2019-11-28
RU2017131447A3 (enExample) 2021-01-14
CA2486539C (en) 2012-03-13
ATE353334T1 (de) 2007-02-15
RU2746132C3 (ru) 2021-08-02
ES2280759T3 (es) 2007-09-16
PL210304B1 (pl) 2011-12-30
RU2489151C2 (ru) 2013-08-10
LTPA2013008I1 (lt) 2013-05-27
CN102627676A (zh) 2012-08-08
JP2005531588A (ja) 2005-10-20
US20020137903A1 (en) 2002-09-26
BR122017015091B8 (pt) 2021-07-27
RU2643764C2 (ru) 2018-02-05
CN101628905B (zh) 2012-03-21
CY2013013I1 (el) 2015-11-04
CN102627676B (zh) 2014-08-20
DE60311649T2 (de) 2007-11-22
RU2004137489A (ru) 2005-06-27
DK1506211T3 (da) 2007-04-10
CA2486539A1 (en) 2003-12-04
HK1205120A1 (en) 2015-12-11
JP2012207037A (ja) 2012-10-25
NO2022041I1 (no) 2022-10-03
PL373369A1 (en) 2005-08-22
HRP20041084B1 (hr) 2008-06-30
RS51469B (sr) 2011-04-30
CN1653075A (zh) 2005-08-10
CY2013013I2 (el) 2015-11-04
BRPI0311323B8 (pt) 2021-05-25
JP5340077B2 (ja) 2013-11-13
CN101092409A (zh) 2007-12-26
IN2004DE03573A (enExample) 2005-04-01
TWI310770B (en) 2009-06-11
KR20050004161A (ko) 2005-01-12
LU92496I2 (fr) 2014-09-10
MY142499A (en) 2010-11-30
PE20040760A1 (es) 2004-11-20
IS7529A (is) 2004-11-16
TW200404813A (en) 2004-04-01
FR13C0022I1 (fr) 2014-02-03
JP5090621B2 (ja) 2012-12-05
JP5604568B2 (ja) 2014-10-08
JP5584738B2 (ja) 2014-09-03
DE60311649D1 (de) 2007-03-22
HRP20041084A2 (en) 2005-06-30
SI1506211T1 (sl) 2007-10-31
LU92182I2 (fr) 2013-06-17
UA77306C2 (uk) 2006-11-15
LTC1506211I2 (lt) 2023-02-10
LU92182I9 (enExample) 2019-01-04
AU2003237886B2 (en) 2009-02-05
WO2003099836A1 (en) 2003-12-04
BR122017015091B1 (pt) 2018-05-15
JP2014028807A (ja) 2014-02-13
CY1106465T1 (el) 2012-01-25
RU2337916C2 (ru) 2008-11-10
BR0311323A (pt) 2005-03-15
BE2014C041I2 (enExample) 2022-08-09
BE2013C025I2 (enExample) 2022-09-29
RU2643764C9 (ru) 2021-12-15
KR101021752B1 (ko) 2011-03-15
MXPA04011371A (es) 2005-02-14
NO329107B1 (no) 2010-08-23
CN100534997C (zh) 2009-09-02
NO2013007I1 (no) 2013-04-29
AU2003237886A1 (en) 2003-12-12
JP2009275050A (ja) 2009-11-26
EP1506211A4 (en) 2005-08-17
US6515117B2 (en) 2003-02-04
NO2014017I1 (no) 2014-07-09
CY2014025I2 (el) 2015-11-04
ZA200409295B (en) 2006-02-22
FR13C0022I2 (fr) 2014-03-07

Similar Documents

Publication Publication Date Title
ME00091B (me) C-aril glukozid sglt2 inhibitori i postupak za njihovu upotrebu
CA2388818A1 (en) C-aryl glucoside sglt2 inhibitors and method
RU2002126586A (ru) О-арилглюкозидные ингибиторы sglt2 и способ их применения
CA2402894A1 (en) Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and method
JP2004500416A5 (enExample)
US7674913B2 (en) Heterocyclic boronic acid compounds
US6774112B2 (en) Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
RU2007113701A (ru) С-арилгликозидные ингибиторы sglt2, содержащие их фармацевтические композиции и комбинации
US20030087843A1 (en) O-pyrazole glucoside SGLT2 inhibitors and method of use
AU2001249598B2 (en) O-aryl glucoside sglt2 inhibitors and method
JP2007501231A5 (enExample)
JP2006501187A5 (enExample)
RS57756B1 (sr) Formulacije tableta sa dva sloja
IE60426B1 (en) Aminomethyl oxooxazolidinyl aroylbenzene derivatives useful as antibacterial agents
JP2004536070A5 (enExample)
US20200255394A1 (en) Crystalline solid forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oxopropan-2-yl)-4-(4-(2-methyl-5-((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenyl)butanamide and methods of their synthesis
US4555505A (en) Method for the treatment of hyperglycemia using p-aminobenzoate-N-L-rhamnoside
US4380536A (en) Pharmaceutical composition containing para-amino-benzoic acid-N-D-mannoside as an active ingredient
AU2008229787B2 (en) Heterocyclic boronic acid compounds
US4410516A (en) 1-N(αHydroxy-ω-aminoalkanoyl) derivatives of 5,3',4'-trideoxy- or 5,3', 4'-trideoxy-6'-N- methyl- or 5, 3', 4',6"-tetradeoxykannamyci B and production thereof
HK40044941A (en) Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
US4637998A (en) Pharmaceutical composition containing a derivative of para-aminobenzoic acid as an active ingredient
CZ2003332A3 (cs) 13-Substituované methacyklinové sloučeniny
NAKAYAMA et al. SkS P harm. kkS